Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals    HIK   GB00B0LCW083

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

BioCentury - Management tracks: NanoString, Orchard

share with twitter share with LinkedIn share with facebook
share via e-mail
01/18/2018 | 12:20pm CET

Molecular diagnostics company NanoString Technologies Inc. (NASDAQ:NSTG) hired Thomas Bailey as CFO. He was CFO of AgaMatrix Holdings LLC (Salem, N.H.).

Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) hired Frank Thomas as CFO and CBO. He was president and COO at AMAG Pharmaceuticals Inc. (NASDAQ:AMAG).

Generics company Hikma Pharmaceuticals plc (LSE:HIK) hired Surendera Tyagi as group CSO and global head of R&D. He was head of the U.S. Innovation & Development Center at the Fresenius Kabi subsidiary of Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY).

Cancer immunotherapy company Immatics Biotechnologies GmbH (Tübingen, Germany) hired Thomas Ulmer as CFO, effective April 1. He is CFO of the Allergopharma GmbH & Co. KG unit at Merck KGaA (Xetra:MRK).

Antibody-drug conjugate (ADC) developer Glythera Ltd. (Newcastle upon Tyne, U.K.) hired Robert Lutz as CSO. He was VP of translation research and development at ImmunoGen Inc. (NASDAQ:IMGN).

Genomics company Sequence Bio Inc. (Newfoundland, Canada) hired Michael Phillips as CSO. He was VP of genomics at Genomics Medicine Ireland Ltd. (Dublin, Ireland).

Biomanufacturing company Selexis S.A. (Geneva, Switzerland) appointed Alberto Garotti CFO. He was president at Evolve Consulting S.a.r.l. (Coppet, Switzerland).

Diagnostic company Immucor Inc. (Norcross, Ga.) hired Avi Pelossof as president and CEO. He succeeds Jeffrey Binder, who will remain chairman. Pelossof was the global president for the infectious disease business of Alere Inc., which Abbott Laboratories (NYSE:ABT) acquired last year.


(C) 2018 M2 COMMUNICATIONS, source M2 PressWIRE

share with twitter share with LinkedIn share with facebook
share via e-mail
01/18 BIOCENTURY - MANAGEMENT TRACKS : NanoString, Orchard
01/15 Drugmaker Dermapharm gears up for likely first German IPO of 2018
2017 HIKMA PHARMACEUTICALS : South Korea’s Celltrion ink MENA product launch de..
2017 Aldermore Appoints Pat Butler Chairman Upon Completion of FirstRand Takeover
2017 HIKMA PHARMACEUTICALS : Ventures participates in a $20.5 million Series C round ..
2017 HIKMA PHARMACEUTICALS : Ventures invests in biolinq, the next generation minimal..
2017 HIKMA PHARMACEUTICALS : Ventures invests in Biolinq
2017 HIKMA PHARMACEUTICALS : Holding(s) in Company
2017 FTSE recoups early losses as cyclicals recover
2017 HIKMA PHARMACEUTICALS : JHCO sends three-truck humanitarian aid convoy to Gaza
More news
News from SeekingAlpha
2017 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q2 2017 Results - Earning..
2017 Hikma Pharmaceuticals plc. 2017 Q2 - Results - Earnings Call Slides
2017 Hikma Pharmaceuticals reports 1H results
2017 Jazz Keeps The Narcolepsy Market Awake
2017 'MAJOR' REPRIEVE NUMBER TWO : Another Stumble For GlaxoSmithKline's Advair Block..
Financials ($)
Sales 2017 1 940 M
EBIT 2017 343 M
Net income 2017 166 M
Debt 2017 496 M
Yield 2017 2,13%
P/E ratio 2017 19,05
P/E ratio 2018 18,00
EV / Sales 2017 1,97x
EV / Sales 2018 1,85x
Capitalization 3 327 M
Duration : Period :
Hikma Pharmaceuticals Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Technical analysis trends HIKMA PHARMACEUTICALS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 14
Average target price 15,5 $
Spread / Average Target 12%
EPS Revisions
Said Samih Taleb Darwazah Chairman & Chief Executive Officer
Khalid Walid Hosni Nabilsi Chief Financial Officer
Ibrahim Jalal Senior Vice President-Technical Affairs
Mazen Samih Taleb Darwazah Executive Vice Chairman & CEO-MENA Region
Mohammed Ali Khaldoun Al-Husry Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.20%394 704
NOVARTIS0.61%224 711
PFIZER2.65%220 487
ROCHE HOLDING LTD.-5.40%210 743
MERCK AND COMPANY10.24%166 723